- Codexis, Inc. (CDXS)
Codexis offers scalable and efficient enzymatic processes for siRNA manufacturing With multiple enzymatic pathways to synthesize siRNA, you can choose the option that best meets your needs
- About Us :: Codexis, Inc. (CDXS)
Codexis is uniquely positioned to expand this development by providing enzymatically synthesized siRNA constructs Our siRNA is manufactured in an aqueous (water-based) solution, which drives down cost and avoids heavy use of toxic solvents
- FAQ :: Codexis, Inc. (CDXS)
Codexis Inc is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics
- Company Info :: Codexis, Inc. (CDXS)
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes
- Investors :: Codexis, Inc. (CDXS)
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the . . .
Codexis enzymatically synthesized the full-length sense and antisense strands of the molecule, including the enzymatic incorporation of a tissue-targeting moiety to the sense strand
- Enzyme Screening Kits Panels :: Codexis, Inc. (CDXS)
Our portfolio of Biocatalysts, Screening Kits and Recycling Enzymes Codexis offers a full range of quality enzymes and screening kits to help you meet your sustainability goals and lower your cost-in-use
- Codexis Reports First Quarter 2025 Financial Results
“Codexis finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flow positivity by the end of 2026,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis
|